ELOX Eloxx Pharmaceuticals, Inc.
Price Chart
Executive Summary
Eloxx Pharmaceuticals' S-1 registration statement (File No. 333-295651) became effective on June 8, 2026, clearing the way for the company to proceed with its public offering of common stock and pre-funded warrants. The offering is expected to raise approximately $54.2 million in net proceeds to fund Phase 2b and Phase 2 trials of exaluren for Alport syndrome and ADPKD, contingent upon Nasdaq uplisting approval. This is a critical capital event for a company currently trading on the OTC market with a going concern qualification.
Actionable Insight
The effectiveness removes the last regulatory hurdle for the offering. Monitor for pricing announcement (typically 1-2 days post-effectiveness) and Nasdaq uplisting approval. The stock may trade with elevated volatility as the offering price and dilution terms are finalized.
Key Facts
- S-1 registration (File No. 333-295651) declared effective by SEC on June 8, 2026.
- Offering includes 2,730,000 shares of common stock and pre-funded warrants to purchase up to 2,770,000 shares.
- Estimated net proceeds of approximately $54.2 million.
- Proceeds intended to fund Phase 2b trial of exaluren in Alport syndrome (topline data mid-2027) and Phase 2 trial in ADPKD (topline data mid-2028).
- Offering is contingent upon Nasdaq uplisting approval; company currently trades on OTC Pink Limited Market.
- Company has a going concern qualification and was previously delisted from Nasdaq in 2023.
Financial Impact
Approximately $54.2 million in net proceeds from the offering.
Risk Factors
- Dilution from the issuance of up to 5.5 million shares (including pre-funded warrants).
- Nasdaq uplisting approval is not guaranteed; failure would likely scuttle the offering.
- Going concern qualification remains unless the offering closes successfully.
- Clinical trial risk: exaluren Phase 2b data not expected until mid-2027.
Market Snapshot
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| EFFECT Filing (Primary) | 9999999995-26-001918 |
| Document: 9999999995-26-001918-index.html | 9999999995-26-001918 |
| Document: 9999999995-26-001918.txt | 9999999995-26-001918 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 9, 2026
4d ago
|
EFFECT
| $6.20 awaiting T+1 | awaiting T+1 | — | $13.52 (+118.06%) |
|
Jun 4, 2026
8d ago
|
S-1/A
| $6.20 awaiting T+1 | awaiting T+1 | — | $13.52 (+118.06%) |
|
Jun 1, 2026
11d ago
|
S-1/A
| $1.51 $10.00 | ▲ +562.25% | ▲ +562.97% | $13.52 (+795.36%) |
|
Jun 1, 2026
12d ago
|
8-K
| $4.07 $1.51 | ▼ −62.90% | ▼ −63.04% | $13.52 (+232.19%) |
|
May 7, 2026
5w ago
|
S-1
| $1.43 $1.43 | ▼ −0.08% | ▼ −0.30% | $13.52 (+844.73%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access